Insufficient Tuberculosis Treatment Leads to Earlier and Higher Mortality in Individuals Co-infected with HIV in Southern China: a Cohort Study

Overview

Journal BMC Infect Dis

Publisher Biomed Central

Specialty Infectious Diseases

Date 2020 Nov 23

PMID 33225919

Citations 5

Authors

Zhigang Zheng

Eric J Nehl

Chongxing Zhou

Jianjun Li

Zhouhua Xie

Zijun Zhou

Hao Liang

Affiliations

Soon will be listed here.

Abstract

Background: Tuberculosis (TB) and Acquired Immune Deficiency Syndrome (AIDS) are leading causes of death globally. However, little is known about the long-term mortality risk and the timeline of death in those co-infected with human immunodeficiency virus (HIV) and Mycobacterium tuberculosis (MTB). This study sought to understand the long-term mortality risk, factors, and the timeline of death in those with HIV-Mycobacterium tuberculosis (MTB) coinfection, particularly in those with insufficient TB treatment.

Methods: TB-cause specific deaths were classified using a modified 'Coding of Cause of Death in HIV' protocol. A longitudinal cross-registration-system checking approach was used to confirm HIV/MTB co-infection between two observational cohorts. Mortality from the end of TB treatment (6 months) to post-treatment year (PTY) 5 (60 months) was investigated by different TB treatment outcomes. General linear models were used to estimate the mean mortality at each time-point and change between time-points. Cox's proportional hazard regressions measured the mortality hazard risk (HR) at each time-point. The Mantel-Haenszel stratification was used to identify mortality risk factors. Mortality density was calculated by person year of follow-up.

Results: At the end point, mortality among patients with HIV/MTB coinfection was 34.7%. From the end of TB treatment to PTY5, mortality and loss of person years among individuals with TB treatment failure, missing, and adverse events (TBFMA) were significantly higher than those who had TB cure (TBC) and TB complete regimen (TBCR). Compared to individuals with TBC and with TBCR, individuals with TBFMA tended to die earlier and their mortality was significantly higher (HR = 3.0, 95% confidence interval: 2.5-3.6, HR = 2.9, 95% CI: 2.5-3.4, P < 0.0001). Those who were naïve to antiretroviral therapy, were farmers, had lower CD4 counts (≤200 cells/μL) and were ≥ 50 years of age were at the highest risk of mortality. Mortality risk for participants with TBFMA was significantly higher across all stratifications except those with a CD4 count of ≤200 cells/μL.

Conclusions: Earlier and long-term mortality among those with HIV/MTB co-infection is a significant problem when TB treatment fails or is inadequate.

Citing Articles

Burden of mortality and its predictors among TB-HIV co-infected patients in Ethiopia: Systematic review and meta-analysis.

Kassaw A, Kefale D, Aytenew T, Azmeraw M, Agimas M, Zeleke S PLoS One. 2024; 19(11):e0312698.

PMID: 39509354 PMC: 11542784. DOI: 10.1371/journal.pone.0312698.

Diagnosis and Treatment of Skipped Multifocal Spinal Tuberculosis Lesions.

Na S, Lyu Z, Zhang S Orthop Surg. 2023; 15(6):1454-1467.

PMID: 37186216 PMC: 10235186. DOI: 10.1111/os.13744.

Treatment outcome and its associated factors among HIV-MTB co-infected patients in Sichuan, China: A retrospective study.

Yang N, Chen C, He J, Li J, Zhong Y Medicine (Baltimore). 2022; 101(48):e32006.

PMID: 36482608 PMC: 9726276. DOI: 10.1097/MD.0000000000032006.

Time trends in tuberculosis mortality across the BRICS: an age-period-cohort analysis for the GBD 2019.

Zou Z, Liu G, Hay S, Basu S, Belgaumi U, Dhali A EClinicalMedicine. 2022; 53:101646.

PMID: 36147625 PMC: 9486016. DOI: 10.1016/j.eclinm.2022.101646.

Medical Care for Tuberculosis-HIV-Coinfected Patients in Russia with Respect to a Changeable Patients' Structure.

Frolova O, Butylchenko O, Gadzhieva P, Timofeeva M, Basangova V, Petrova V Trop Med Infect Dis. 2022; 7(6).

PMID: 35736965 PMC: 9228798. DOI: 10.3390/tropicalmed7060086.

References

Selwyn P, Hartel D, Lewis V, Schoenbaum E, Vermund S, Klein R . A prospective study of the risk of tuberculosis among intravenous drug users with human immunodeficiency virus infection. N Engl J Med. 1989; 320(9):545-50. DOI: 10.1056/NEJM198903023200901. View

Holmes C, Wood R, Badri M, Zilber S, Wang B, Maartens G . CD4 decline and incidence of opportunistic infections in Cape Town, South Africa: implications for prophylaxis and treatment. J Acquir Immune Defic Syndr. 2006; 42(4):464-9. DOI: 10.1097/01.qai.0000225729.79610.b7. View

Corbett E, Charalambous S, Moloi V, Fielding K, Grant A, Dye C . Human immunodeficiency virus and the prevalence of undiagnosed tuberculosis in African gold miners. Am J Respir Crit Care Med. 2004; 170(6):673-9. DOI: 10.1164/rccm.200405-590OC. View

Lopez-Gatell H, Cole S, Hessol N, French A, Greenblatt R, Landesman S . Effect of tuberculosis on the survival of women infected with human immunodeficiency virus. Am J Epidemiol. 2007; 165(10):1134-42. DOI: 10.1093/aje/kwk116. View

Saunders N, Trivedi U, Thomson M, Doig C, Laurenson I, Blaxter M . Deep resequencing of serial sputum isolates of Mycobacterium tuberculosis during therapeutic failure due to poor compliance reveals stepwise mutation of key resistance genes on an otherwise stable genetic background. J Infect. 2011; 62(3):212-7. DOI: 10.1016/j.jinf.2011.01.003. View

Lawn S, Kranzer K, Edwards D, McNally M, Bekker L, Wood R . Tuberculosis during the first year of antiretroviral therapy in a South African cohort using an intensive pretreatment screening strategy. AIDS. 2010; 24(9):1323-8. PMC: 3772277. DOI: 10.1097/QAD.0b013e3283390dd1. View

Ji Y, Liang P, Shen J, Sun J, Yang J, Chen J . Risk factors affecting the mortality of HIV-infected patients with pulmonary tuberculosis in the cART era: a retrospective cohort study in China. Infect Dis Poverty. 2018; 7(1):25. PMC: 5870507. DOI: 10.1186/s40249-018-0405-8. View

Gelmanova I, Keshavjee S, Golubchikova V, Berezina V, Strelis A, Yanova G . Barriers to successful tuberculosis treatment in Tomsk, Russian Federation: non-adherence, default and the acquisition of multidrug resistance. Bull World Health Organ. 2007; 85(9):703-11. PMC: 2636414. DOI: 10.2471/blt.06.038331. View

Naidoo K, Yende-Zuma N, Padayatchi N, Naidoo K, Jithoo N, Nair G . The immune reconstitution inflammatory syndrome after antiretroviral therapy initiation in patients with tuberculosis: findings from the SAPiT trial. Ann Intern Med. 2012; 157(5):313-24. PMC: 3534856. DOI: 10.7326/0003-4819-157-5-201209040-00004. View

10.

Meintjes G, Wilkinson K, Rangaka M, Skolimowska K, van Veen K, Abrahams M . Type 1 helper T cells and FoxP3-positive T cells in HIV-tuberculosis-associated immune reconstitution inflammatory syndrome. Am J Respir Crit Care Med. 2008; 178(10):1083-9. PMC: 2643222. DOI: 10.1164/rccm.200806-858OC. View

11.

Day C, Abrahams D, Lerumo L, van Rensburg E, Stone L, Orie T . Functional capacity of Mycobacterium tuberculosis-specific T cell responses in humans is associated with mycobacterial load. J Immunol. 2011; 187(5):2222-32. PMC: 3159795. DOI: 10.4049/jimmunol.1101122. View

12.

Meintjes G, Lawn S, Scano F, Maartens G, French M, Worodria W . Tuberculosis-associated immune reconstitution inflammatory syndrome: case definitions for use in resource-limited settings. Lancet Infect Dis. 2008; 8(8):516-23. PMC: 2804035. DOI: 10.1016/S1473-3099(08)70184-1. View

13.

Zheng Z, Tang Z, Lu Q, Wei H, Geng W . [Influential factors analysis on the survival time of patients infected with tuberculosis and HIV]. Zhonghua Yu Fang Yi Xue Za Zhi. 2016; 49(10):907-13. View

14.

Laureillard D, Marcy O, Madec Y, Chea S, Chan S, Borand L . Paradoxical tuberculosis-associated immune reconstitution inflammatory syndrome after early initiation of antiretroviral therapy in a randomized clinical trial. AIDS. 2013; 27(16):2577-86. DOI: 10.1097/01.aids.0000432456.14099.c7. View

15.

Bourgarit A, Carcelain G, Samri A, Parizot C, Lafaurie M, Abgrall S . Tuberculosis-associated immune restoration syndrome in HIV-1-infected patients involves tuberculin-specific CD4 Th1 cells and KIR-negative gammadelta T cells. J Immunol. 2009; 183(6):3915-23. DOI: 10.4049/jimmunol.0804020. View

16.

Ravimohan S, Tamuhla N, Steenhoff A, Letlhogile R, Makutu D, Nfanyana K . Early immunologic failure is associated with early mortality among advanced HIV-infected adults initiating antiretroviral therapy with active tuberculosis. J Infect Dis. 2013; 208(11):1784-93. PMC: 3814836. DOI: 10.1093/infdis/jit368. View

17.

Ji Y, Wang Z, Shen J, Chen J, Yang J, Qi T . Trends and characteristics of all-cause mortality among HIV-infected inpatients during the HAART era (2006-2015) in Shanghai, China. Biosci Trends. 2017; 11(1):62-68. DOI: 10.5582/bst.2016.01195. View

18.

Gao L, Zhou F, Li X, Jin Q . HIV/TB co-infection in mainland China: a meta-analysis. PLoS One. 2010; 5(5):e10736. PMC: 2873981. DOI: 10.1371/journal.pone.0010736. View

19.

Sharma S, Turaga K, Balamurugan A, Saha P, Pandey R, Jain N . Clinical and genetic risk factors for the development of multi-drug resistant tuberculosis in non-HIV infected patients at a tertiary care center in India: a case-control study. Infect Genet Evol. 2003; 3(3):183-8. DOI: 10.1016/s1567-1348(03)00086-8. View

20.

Luetkemeyer A, Kendall M, Nyirenda M, Wu X, Ive P, Benson C . Tuberculosis immune reconstitution inflammatory syndrome in A5221 STRIDE: timing, severity, and implications for HIV-TB programs. J Acquir Immune Defic Syndr. 2013; 65(4):423-8. PMC: 3943693. DOI: 10.1097/QAI.0000000000000030. View